Lupin to get booster from USFDA nod

| Updated on January 22, 2018 Published on November 24, 2015


Shares of Lupin will remain in focus, following the company receiving approval from the USFDA for its generic version of Warner Chilcott’s oral contraceptive tablets Loestrin in two strengths. Lupin Pharmaceuticals Inc would shortly commence promotion of the product in the US. Warner Chilcott’s Loestrin Fe 1/20 had sales of $139.7 million and Loestrin Fe 1.5/30 $55.5 million in the year ended September, according to data from IMS Health.

Published on November 24, 2015
This article is closed for comments.
Please Email the Editor